WINTON GROUP Ltd Acquires Shares of 11,666 Elanco Animal Health Incorporated (NYSE:ELAN)

WINTON GROUP Ltd bought a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 11,666 shares of the company’s stock, valued at approximately $141,000.

Other hedge funds also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB purchased a new stake in Elanco Animal Health during the third quarter worth about $35,000. Jones Financial Companies Lllp increased its stake in shares of Elanco Animal Health by 95.6% during the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company’s stock worth $51,000 after purchasing an additional 2,059 shares during the last quarter. SRS Capital Advisors Inc. raised its holdings in shares of Elanco Animal Health by 221.2% in the 4th quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company’s stock worth $60,000 after purchasing an additional 3,411 shares during the period. MRP Capital Investments LLC purchased a new position in Elanco Animal Health in the fourth quarter valued at approximately $61,000. Finally, Blue Trust Inc. grew its holdings in Elanco Animal Health by 47.7% during the fourth quarter. Blue Trust Inc. now owns 5,862 shares of the company’s stock valued at $71,000 after purchasing an additional 1,894 shares during the period. 97.48% of the stock is currently owned by institutional investors.

Insider Transactions at Elanco Animal Health

In related news, Director Lawrence Erik Kurzius acquired 10,000 shares of the company’s stock in a transaction dated Tuesday, March 11th. The stock was bought at an average cost of $10.20 per share, with a total value of $102,000.00. Following the acquisition, the director now owns 111,459 shares of the company’s stock, valued at approximately $1,136,881.80. The trade was a 9.86 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.57% of the stock is owned by insiders.

Elanco Animal Health Stock Performance

NYSE ELAN opened at $10.49 on Tuesday. The company’s 50 day simple moving average is $11.20 and its two-hundred day simple moving average is $12.39. The stock has a market capitalization of $5.19 billion, a PE ratio of 26.21, a P/E/G ratio of 2.50 and a beta of 1.44. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. Elanco Animal Health Incorporated has a 1 year low of $10.03 and a 1 year high of $18.80.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.01). The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. Elanco Animal Health’s quarterly revenue was down 1.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.08 EPS. Analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ELAN. Barclays lowered their target price on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Morgan Stanley dropped their price objective on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 26th. Leerink Partnrs upgraded shares of Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. Stifel Nicolaus dropped their price target on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday, February 21st. Finally, UBS Group lowered their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Wednesday, February 26th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $15.17.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.